Strength of leadership

600K+ Devices implanted | 2,000+ Limbs studied

With more than 10 years of performance, over 600,000 devices implanted, and over 2,000 limbs studied, the GORE® PROPATEN® Vascular Graft is a leading prosthetic bypass graft solution for proven clinical performance and low cumulative cost of care.


GORE® PROPATEN® Vascular Graft

Above-knee bypass primary patency
Above-knee bypass primary patency

Above-knee data

Below-knee bypass primary patency
Below-knee bypass primary patency

Below-knee data

* Overall weighted average primary patency is based on data from 15 peer-reviewed publications meeting pre-determined inclusion criteria.


Proven patency

By substantially reducing acute graft thrombosis within hours after implantation, the CBAS Heparin Surface on the GORE® PROPATEN® Vascular Graft provides clinical benefits that standard ePTFE grafts do not.1


Fewer occlusions
50% reduction in risk of graft occlusion compared to standard ePTFE in critical limb ischemia (CLI) patients.2


Improved patient outcomes
Higher primary and secondary patency, and higher limb salvage for below-knee bypass compared to standard ePTFE from 1–3 years.3

Improved clinical outcomes

* Weighted average of GORE® PROPATEN® Vascular Graft data.

** Weighted average of standard ePTFE data.


Measurable value

The GORE® PROPATEN® Vascular Graft is a leading prosthetic bypass graft solution for proven clinical performance and low cumulative cost of care.


 

Low treatment cost

GORE® PROPATEN® Vascular Graft: long-term value

28% Patients

Improvement in amputation-free survival

36% Physicians

Decrease in revision procedures

38% Providers

Decrease in average costs

† Based on the 3-year published clinical performance and economic model.


Lasting thromboresistance. Proven technology.7

CBAS Heparin Surface

The CBAS Heparin Surface of the GORE® PROPATEN® Vascular Graft consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin’s anticoagulant activity.


Proven

Heparin availability

Performance-ready heparin active site.4, 6


Proven

Heparin bioactivity

Unmatched, persistent ability to take up antithrombin.1, 5


Proven

Lasting thromboresistance

Improved surface hemocompatibility resulting from heparin availability and bioactivity.1, 4–7




Sustained heparin bioactivity8

In vivo canine carotid artery interposition model

The CBAS Heparin Surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft (top) remains free of thrombus, while the 3 mm diameter control ePTFE graft (bottom) is covered with thrombus in an acute two-hour in vivo canine carotid artery interposition model.

Learn more about CBAS

  1. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437.
  2. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian PROPATEN® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomized clinical controlled multi-centre trial. European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.
  3. GORE® PROPATEN® Vascular Graft. W. L. Gore & Associates Web site. https://www.goremedical.com/propaten/references. Accessed May 15, 2019.
  4. Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: impact of immobilization chemistry on hemocompatibility and protein adsorption. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2014;102(8):1817-1824.
  5. Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic canine femoral artery bypass model. Annals of Vascular Surgery 2018;49:295-303.
  6. Biran R, Pond D. Heparin coatings for improving blood compatibility of medical devices. Advanced Drug Delivery Reviews 2017;112:12-23.
  7. CBAS Heparin Surface. W. L. Gore & Associates Web site. https://www.goremedical.com/cbas/references. Accessed May 3, 2019.
  8. Biran R. Heparin Activity and Concentration Values from 52 and 96 Month Duration Clinical Explants of the GORE® PROPATEN® Vascular Graft. Flagstaff, AZ: W.L. Gore & Associates, Inc; 2011 [Work plan]. WP104647

GORE PROPATEN Vascular Graft